Moderna collected $3.1 billion in 2024 Spikevax sales and $25 million from its newer mRESVIA. At its peak in 2022, Spikevax brought in $18.4 billion for the company.

The most impactful development was the rapid success of Moderna's COVID-19 vaccine, Spikevax, which witnessed massive demand during the pandemic. Starting in early 2021, regulatory approvals from ...

Investor interest in the biotechnology industry hit a fever pitch in 2021 around the time Moderna launched Spikevax, its COVID-19 vaccine. The company's sales surged to $18.5 billion in 2021 from ...

In December 2020, both Moderna's Spikevax and Pfizer / BioNTech's Comirnaty COVID vaccines received emergency use authorization (“EUA”) in the US. Both used a pioneering new mechanism of ...

Moderna recently faced significant legal challenges with five international lawsuits from Genevant Sciences and Arbutus Biopharma targeting its LNP technology used in products like Spikevax®.

Pfizer and BioNTech earned more than $3.3 billion in revenue from global sales of their vaccine Comirnaty last year, while Moderna earned $3.2 billion from its vaccine Spikevax, according to ...

A big legal victory across the Atlantic Ocean was the news propelling Moderna (NASDAQ ... best known as the producer of the Spikevax COVID vaccine, pushed its stock nearly 16% higher during ...

In its fourth quarter of 2025, Moderna reported $923 million in Spikevax sales, comprised of $244 million in the United States and $679 million internationally. Spikevax generated $3.1 billion in ...

Moderna has filed complaints in the US and Germany claiming that the mRNA technology used to make Pfizer and BioNTech's Comirnaty vaccine infringes multiple patents that cover its own Spikevax shot.

The CEO of Moderna Inc. (NASDAQ: MRNA) just purchased $5 million of stock in the open market. This is very significant since most of the insider trades have been sales for the past year.